Background: The viral RNA-dependent RNA polymerase (RdRp) enzymes of the Flaviviridae family are essential for viral replication and are logically important targets for development of antiviral therapeutic agents. Zika virus (ZIKV) is a rapidly re-emerging human pathogen for which no vaccine or antiviral agent is currently available.
Introduction
Zika virus (ZIKV) belongs to the family Flaviviridae, a group of enveloped positive-sense single-stranded RNA viruses and is transmitted by mosquitos, primarily the daytime-active female Aedes aegypti.
1,2 Although ZIKV was first isolated from a sentinel rhesus monkey placed in the Zika Forest near Lake Victoria in Uganda in 1947, 3 outbreaks of ZIKV have been reported since 2007 on Yap Island, the Federated States of Micronesia, and in 2013 in New Caledonia, the Cook Islands, French Polynesia and Easter Island. [4] [5] [6] Most recently, a widespread Zika epidemic has spread from Brazil to other parts of South and North America. 6, 7 In February 2016, the WHO declared Zika to be a Public Health Emergency of International Concern (PHEIC). 8, 9 It is estimated that 80% of ZIKV infections are asymptomatic. 10, 11 Recent studies have shown significant cellular death of neural stem cells once infected with ZIKV and animal models have demonstrated that ZIKV infection can lead to microcephaly in mice, 12, 13 making clear that ZIKV is an emergent neuropathological agent.
14 Currently, there is no effective antiviral treatment for any flavivirus, including ZIKV and dengue virus (DENV), and no vaccine is available for either West Nile virus (WNV) or ZIKV.
ZIKV is a small enveloped virus, similar to other flavivirus structures, 15, 16 and possesses a single-stranded positive-sense RNA genome of 11 kb, which encodes a single polyprotein flanked by 5 0 and 3 0 untranslated regions (UTRs). [17] [18] [19] This polyprotein of 3400 amino acids undergoes proteolytic cleavage by viral serine and cellular furin proteases to generate the capsid (C) protein, the precursor of the membrane protein (prM), and the envelope protein (E), as well as seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). 18, 19 The NS5 protein is 900 amino acids long and includes a methyltransferase domain at its N terminus and an RNA-dependent RNA polymerase (RdRp) domain at the C terminus. 1 Viral RdRps are essential for viral replication and are a significant target for development of direct-acting antiviral (DAA) agents, such as those that target the NS5B of hepatitis C virus (HCV), and, indeed, both nucleos(t)ide inhibitors (NIs) and non-nucleoside inhibitors (NNIs) have been approved for treatment of HCV infections. [20] [21] [22] NS5 is the most conserved flavivirus protein, and several crystal structures of flavivirus NS5 and/or the polymerase domain have been solved. [23] [24] [25] [26] [27] [28] Sequence analysis of the NS5 polymerase gene of ZIKV (data not shown) has revealed a high degree of homology with six conserved RdRp motifs of other flaviviruses, termed A-F, which play key roles in binding of each of RNA, nucleoside triphosphate (NTP) and metal ions as well as in catalysis. 28 The amino acids in the catalytic site of ZIKV RdRp are located within motif A (D536) and a catalytic GDD triad at position 665-667 (D666, D667) in motif C. The two latter aspartate residues are involved in the coordination of two divalent metal ion cofactors that are essential to the catalytic process, i.e. the 'two-metal-ion mechanism'. 29 Viral RdRp inhibitors approved for the clinic include NIs that function as chain terminators of nascent nucleic acid production and NNIs. The NIs require intracellular phosphorylation by cellular kinases to a 5 0 -triphosphate form, following which they bind at the enzyme's active site and compete with natural substrates for incorporation. [30] [31] [32] By contrast, NNIs do not require intracellular activation and interfere with the chemical step of RNA synthesis by binding to allosteric sites remote from the active site of the RdRp. [32] [33] [34] [35] NIs have been shown to be effective against HCV, 32 DENV, 33 tick-borne encephalitis virus (TBEV), 36 WNV 37 and yellow fever virus (YFV). 38 Sofosbuvir was the first anti-HCV NI to be approved by the FDA in December 2013 and has a high genetic barrier to resistance as well as an excellent safety profile. 32 It is phosphorylated intracellularly to 2 0 -C-methyl-2 0 -fluoro-UTP. Viral RdRps employ a mechanism for nucleotidyl transfer that involves two metal ions at the active site. 39 Metal-chelating agents represent an important NNI class of enzyme inhibitors [29] [30] [31] [32] [33] and chelation of the divalent metal ion cofactors of HIV integrase has led to the design and approval of raltegravir, elvitegravir and dolutegravir. 31 Metal chelation has also been effective in regard to inhibition of HCV polymerase 34, 35 and influenza PA endonuclease 33 and the RdRp of DENV. 40 In this study, we describe the expression, purification and characterization of ZIKV RdRp. We show that sofosbuvir triphosphate and a pyridoxine-derived small-molecule inhibitor, DMB213, can efficiently inhibit ZIKV RdRp activity in filter-binding enzyme assays and have verified these results in cell-based assays. Furthermore, we show that an S604T substitution in the ZIKV RdRp, corresponding to S600T in DENV RdRp and S282T in HCV RdRp, both of which were shown to be resistant to NIs, 30, 32, 41, 42 conferred resistance to sofosbuvir, but not to DMB213. Thus, we have established novel RdRp assays for screening inhibitors that target ZIKV NS5 polymerase and have shown that both NI and NNI strategies could potentially be pursued as part of anti-ZIKV drug development.
Materials and methods

Compounds and nucleic acids
All DNA and RNA oligonucleotides used were purchased from Integrated DNA Technologies (IDT DNA, Coralville, IA, USA). Poly(rC) RNA and poly(rA)/ oligo(dT) [12] [13] [14] [15] [16] [17] [18] were obtained from Midland Certified Reagent Company (Midland, TX, USA).
The ZIKV mini-genome (ZMG) consists of the first 228 nt of the 5 0 end of genomic RNA plus three guanines and the last 533 nt at the 3 0 end. ZMG DNA was derived by use of three PCR reactions that targeted the 5 0 and 3 0 ends of cDNA fragments that were reverse transcribed from ZIKV genome RNA (GenBank accession number KF993678, strain PLCal_ZV), using procedures employed for construction of the DENV mini-genome. 43 The first PCR was performed using the ZIKV 5 0 end the cDNA fragment and employed forward primer ZVOPT7F [5 0 -TAATACGACTCACTATAGGGAGTTGTTGATCTGTGTG-3' (the T7 promoter and the three extra guanines are underlined)] and the reverse primer ZVOPR1 [5 0 -ATCACCTATGATCCTGCGCACCATGTTGACCCAGCAGAAGTC CGGC-3 0 (the overlapped region with the 5 0 end of the product from the second PCR is underlined)]. The second PCR was performed using the ZIKV 3 0 -end cDNA fragment and primers ZVMGF2 (5 0 -AACATGGTGCGCAGGATC-3 0 ) and ZV3 0 UTRR (5 0 -AGACCCATGGATTTCCCCACACCGGCCG-3 0 ). The PCR products of PCRs 1 and 2 were purified through 1% agarose gel electrophoresis, annealed and then used as PCR templates using primers ZVOPT7F and ZV3 0 UTRR. The DNA product was purified through 1% agarose gel electrophoresis and used as a DNA template for in vitro transcription to produce a 764 nt RNA template containing the 3 0 end of genomic ZIKV RNA and three extra guanines upstream of its 5 0 terminus, using an Ambion T7-MEGAscript kit (Thermo Fisher Scientific Inc., Mississauga, ON, Canada) (using protocols provided by the manufacturer).
Sofosbuvir and its active form, sofosbuvir triphosphate, were obtained from Gilead Sciences Inc. 3 0 -dGTP was obtained from TriLink BioTechnologies (San Diego, CA, USA). Mycophenolic acid was obtained from Sigma-Aldrich (Markham, ON, Canada).
Preparation of DMB213
DMB213 ( Figure 1 ) was identified by screening a small library of pyridoxinederived small-molecule compounds 44 that were constructed through drug-design protocols aimed at chelating the divalent metal ions from the catalytic sites of viral enzymes such as HIV integrase and DENV RdRp. 40, 44 Construction of ZIKV NS5 polymerase bacterial expression plasmids and expression of Zika NS5 polymerase
The gene encoding the ZIKV NS5 polymerase domain was synthesized via GeneArt Gene Synthesis (Thermo Fisher Scientific Inc.), based on the ZIKV genome sequence (GenBank accession number KU321639.1). 45 BspHI and XhoI were used to digest the 5 0 and 3 0 ends, respectively, and after digestion with BspHI and XhoI, the fragment was cloned into the NcoI and XhoI sites of pET28b vector (Novagen). The final construct (pET28bZVNS5PolcHis6) was confirmed by sequencing and used for expression and purification of the recombinant ZIKV RNA polymerase domain containing a carboxyl-terminus hexahistidine tag in Escherichia coli. The amino acid substitutions S604T in motif B and mGDD (containing the D666A/D667A double mutations) in motif C were introduced into ZIKV virus NS5 polymerase using the Quick-change mutagenesis kit (Agilent Technologies Canada Inc., Mississauga, ON, Canada) Xu et al.
and pET28bZVNS5PolcHis6 DNA as template. The highly conserved motif B of RdRp in ZIKV NS5 'Q 601 RS 604 GQVVTYALNTF 615 ' is identical to those of WNV and Japanese encephalitis virus. 27, 46 Expression and purification of recombinant Zika NS5 polymerase were as recently described for the polymerase of DENV. 46 Establishment of a de novo RdRp assay using recombinant ZIKV NS5 polymerase and heteropolymeric ZIKV mini-genomic RNA Flaviviridae RdRp enzymes carry out RNA synthesis through a de novo initiation mechanism.
2, 47 We evaluated the ZIKV NS5 polymerase in reactions employing ZMG RNA as template in order to screen NIs and NNIs. Optimal reaction conditions were similar to those previously described for the RdRp of DENV. 46 Establishment of a primer-dependent RdRp assay using recombinant ZIKV NS5 polymerase and homopolymeric RNA Flaviviridae RdRp enzymes can efficiently use homopolymeric RNA template as an efficient substrate. 46 ,48 Therefore, we established a ZIKV primer-dependent RdRp filter-binding assay that employed homopolymeric poly (rC) RNA template/rG 13 primer (T/P) as a screen for NNIs. We began with procedures used for DENV RdRp, 46 which were optimized for ZIKV NS5 polymerase. A 20 lM T/P stock solution was prepared by annealing the RNA primer rG 13 to poly(rC) RNA template at an equal molar ratio in a buffer containing 50 mM Tris (pH 8.0) and 50 mM NaCl by heating at 95 C for 5 min, then slowly cooling to room temperature using a heat block. The RdRp reaction mixture contained 20 mM Tris-HCl (pH 6.8), 10 mM NaCl, 0.5 mM TCEP [Tris(2-carboxyethyl)phosphine], 0.001% Igepal-CA630, 5% glycerol, 1 U/lL SUPERase In RNase Inhibitor (Thermo Fisher Scientific Inc.), 0.5 lM T/P poly(rC)/rG 13 C, followed by addition of ice-cold 10% cold trichloroacetic acid (TCA) and 20 mM sodium pyrophosphate, following which the samples were kept on ice for at least 30 min. The precipitated products were processed as described above for the de novo RdRp assay. Calculations of IC 50 values were as described above.
Evaluation of compounds against ZIKV replication in cell culture ZIKV (strain PLCal_ZV) and Huh7 cells (kindly provided by Drs David Safronetz and Gary Kobinger, National Microbiology Laboratory of Canada) were used in our cell-based assays. Huh7 cells were maintained in 10% DMEM supplemented with 4 mM glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin. The TCID 50 of ZIKV was determined by the Promega Viral ToxGlo Assay (Fisher Scientific, Ottawa, ON, Canada) in Huh7 cells. Cell-based assays for evaluation of antiviral activity against ZIKV were performed using the Viral ToxGlo Assay (Fisher Scientific, Ottawa, ON) following the manufacturer's instructions. Zika virus RNA-dependent RNA polymerase inhibitors JAC Evaluation of DMB213 against HIV-1 reverse transcriptase (RT) and integrase activities Subtype B HIV-1 WT RT and that containing the M184V substitution were generated as described previously. 49, 50 A test of the inhibitory effect of DMB213 on HIV-1 RT activity was performed as described. 51 Recombinant subtype B HIV-1 integrase was expressed in and purified from E. coli BL21(DE3) cells as previously published. 52, 53 Using the strand-transfer assay, the susceptibility of HIV recombinant integrase to DMB213 and integrase strand-transfer inhibitors (INSTIs) was assessed in the presence of DMB213 or INSTIs, including dolutegravir, elvitegravir and raltegravir. 52, 53 Molecular modelling A homology model of Zika polymerase was generated using the I-TASSER protein structure prediction server. [54] [55] [56] Previously published structures were obtained through the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (http://www.rcsb.org/pdb/). Molecular modelling was performed using the published lead template of DENV NS5 RdRp (PDB ID: 2J7U). 25 The published structure of HCV NS5B in complex with Mn 2þ and primer template (PDB ID: 4WTA) was also used for the generation of the Zika polymerase homology model. 57 The structure of DMB213 was generated from PubChem Sketcher V2.4 (http://pubchem. ncbi.nlm.nih.gov/edit) and used as a ligand. Minimization of ligand-docked structures was facilitated by the use of a UCSF Chimera (http://www.cgl. ucsf.edu/chimera/), 58 which prepared Zika polymerase and DMB213 as inputs for DOCK calculations, which predict the orientation of the ligand. Docking calculations were performed using AutoDock Vina, 59 The putative positions of Mg 2þ and RNA were superimposed from published structures, i.e. 2J7U and 4WTA, respectively. The homology model was verified by Ramachandran plot analysis to have >97.6% of residues in allowed and favourable orientations.
60,61
Results
Purification and characterization of ZIKV RdRp
Recombinant ZIKV NS5 WT polymerase and RdRp enzymes containing either an S604T substitution and or an mGAA (from mGDD) substitution in the active site were purified to >95% homogeneity under native conditions, as demonstrated by SDS-PAGE (Figure 2a) . For characterization of enzyme activity, the rate of RNA synthesis was analysed by following the incorporation of radiolabelled nucleotide into newly synthesized RNA, which was separated from free radiolabelled nucleotide by TCA precipitation and filtration. Time course experiments were initiated by mixing together 400 nM purified NS5 polymerase with 100 nM RNA in RdRp assay buffer, thus, providing a means of comparing different NS5 polymerases (Figure 2b) .
First, we observed that the S604T substitution caused a diminution in enzyme activity compared with WT, similar to results obtained with the S600T mutation in the DENV NS5 polymerase. The active-site RdRp mutant mGDD was completely devoid of enzyme activity. Thus, we confirmed that ZIKV RdRp activity is associated with the purified NS5 polymerase domain and that the active site GDD motif is essential for this activity. The S604T substitution was introduced into the ZIKV NS5 polymerase domain by site-directed mutagenesis.
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Inhibitory effect of sofosbuvir triphosphate on ZIKV RdRp activity in a de novo RdRp assay
To determine the inhibitory effect of sofosbuvir triphosphate on ZIKV NS5 polymerase activity, we used purified recombinant ZIKV NS5 polymerase and heteropolymeric ZMG RNA substrate in a de novo ZIKV RdRp assay. We observed that sofosbuvir triphosphate was potent against NS5 polymerase activity, with an IC 50 of 7.3 lM (Table 1) . We also observed an enhanced IC 50 value (36 lM) for the S604T-mutated RdRp, suggesting that this substitution conferred 5-fold resistance to sofosbuvir triphosphate relative to WT enzyme. We also showed that 3 0 -dGTP inhibited RdRp activity of WT and S604T mutant enzymes with similar potency, with IC 50 s of 0.7 and 0.8 lM, respectively.
Inhibition of ZIKV polymerase activity by the nonnucleoside DMB213 in a primer-dependent RdRp assay
We used homopolymeric poly rC/rG 13 RNA substrate in an in vitro filter-binding ZIKV RdRp assay to screen a large number of pyridoxine-derived compounds for antiviral activity. While most of these were not active in our analysis, one of them, DMB213, was potent against NS5 polymerase activity with IC 50 of 5.2 lM (Table 2) . We also observed a similar IC 50 value (4.2 lM) for the S604T-mutated RdRp, suggesting that this variant remained susceptible to DMB213 and that sofosbuvir triphosphate and DMB213 possessed different mechanisms of action. The S604T mutant was chosen for this study based on the fact that this residue is highly conserved within the RdRp B motif and was previously shown to confer resistance in HCV to nucleoside analogue inhibitors. As an internal control for the filter-binding RdRp assay, we measured the inhibitory effect of a nucleoside chain terminator 3 0 -dGTP on ZIKV NS5 polymerase. We showed that 3 0 -dGTP inhibited RdRp activities of both WT and the S604T mutant enzymes with similar potencies, with IC 50 s of 0.9 lM ( Table 2 ).
Antiviral activity of sofosbuvir and DMB213 against ZIKV in a cell-based assay
To establish the anti-ZIKV activity and relative toxicities of sofosbuvir and DMB213 in cell culture, we used the Promega Viral ToxGlo Assay and Huh7 cells. ZIKV-infected cells were treated with increasing concentrations of sofosbuvir, DMB213 or mycophenolic acid and protection from cytopathic effect was measured. The broad-spectrum antiviral agent mycophenolic acid was used as a positive control of inhibition of ZIKV replication. Experiments were run in duplicate and the data of three independent experiments are summarized in Table 3 . The data show that both sofosbuvir and DMB213 were able to inhibit ZIKV, with 50% effective concentrations (EC 50 s) of 8.3 and 4.6 lM, respectively (Table 3) , whereas the EC 50 for ZIKV of mycophenolic acid was 0.8 lM, in agreement with a recent report. 62 The 50% cytotoxic concentration (CC 50 ) of DMB213 was 22 lM as assayed in Huh7 cells using the Viral ToxGlo Assay (Table 3) . Thus, the selectivity index (SI) of DMB213 was below that of sofosbuvir and mycophenolic acid. Accordingly, DMB213 is probably more toxic than sofosbuvir and mycophenolic acid.
Effect of NTP concentration on inhibitory potential of DMB213 against ZIKV NS5 polymerase activity DMB213 was designed to be able to chelate divalent metal ions from the active site of ZIKV RdRp; therefore, its binding to the RdRp active site might be competitive with that of natural NTP substrates. Previously, we demonstrated that a compound of this same class, i.e. DMB220, was competitive relative to NTPs. 40 To assess this in primer-dependent RdRp reactions with homopolymeric RNA T/P substrate, we used a variety of GTP concentrations in the presence of increasing concentrations of DMB213. We found that the IC 50 of DMP213 increased as higher concentrations of the GTP substrate were used, which confirms a competitive mechanism of action for DMB213, in agreement with our previous data on DMB220 and DENV (Table 4) .
Inhibitory effects of DMB213 on HIV-1 integrase and RT
To test for specificity, we determined whether DMB213 can inhibit the HIV-1 integrase and RT enzymes, which also require metal ion cofactors at the active sites for catalysis. We observed that DMB213 did not inhibit HIV-1 RT activity at concentrations as high as 100 lM (data not shown). In the integrase strand-transfer assay, DMB213 showed a weak inhibitory effect, with an IC 50 of 13.3 lM in comparison with the IC 50 s of the approved HIV Figure 3 . Docking of DMB213 into the active site of the Zika polymerase homology model. DMB213 docks in close proximity to the active site residues D536, D666 and D667. The active site is shown as surface coloured by standard CPK coloration. Blue represents surface-exposed nitrogen and red represents surface-exposed oxygen groups. The proximal location of Mg 2þ was superimposed into the homology model from the dengue polymerase structure (2J7U) by structure overlay. A short doublestranded RNA was retrieved from the PDB structure 4WTA and overlaid on the homology model structure. Structure visualization was performed using PyMOL. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
Zika virus RNA-dependent RNA polymerase inhibitors JAC integrase inhibitors raltegravir, elvitegravir and dolutegravir, which ranged between 1.6 and 6.8 nM (not shown). Thus, DMB213 possesses apparent specificity for the ZIKV NS5 polymerase.
Molecular docking
Due to the high sequence homology between the Zika and dengue polymerase enzymes, i.e. 67% amino acid identity, we used the dengue polymerase structure as a template to generate a homology model of Zika polymerase. The RMSD (root mean square deviation) calculated using PyMOL between the homology model of Zika polymerase obtained from AutoDock Vina and the published structure of dengue polymerase was 0.331 Å .
Alignment of the active site of the dengue polymerase structure (2J7U) and Zika polymerase model shows that the catalytic domain and catalytic residues of dengue polymerase show good superimposition with those of Zika polymerase, suggesting that the position of Mg2þ is appropriate (Figure 3 ). The Mg2þ ion is close to the expected catalytic position where it is coordinated with residues D536, D666, and D667. DMB213 is also within interaction distance of residues in the catalytic domain (A535, D694, P700 and T702) (not shown). Our docking results are consistent with the observation that DMB213 is a competitive inhibitor of Zika polymerase.
Discussion
This is the first manuscript to report that the NS5 polymerase enzyme of ZIKV can be purified and expressed in E. coli. In addition, we have characterized this enzyme in a number of important ways. First, we have demonstrated that RdRp of Zika displays important cation dependency. Second, we have shown that both NIs and NNIs can be active against Zika replication and RdRp activity. Third, we have documented that this enzyme can display drug resistance based on a mutation at position S604T. This is important as this substitution is equivalent in its placement within ZIKV RNA to that of similar substitutions within the polymerase enzymes of HCV and DENV that are also associated with resistance to antiviral compounds.
There is clearly a compelling need to deal with the devastation that has been caused by epidemics attributable to ZIKV. There is widespread consensus that the best hope for a longterm solution is through the development of a safe and effective vaccine that will prevent infection by Zika in the first place. However, in advance of the development and approval of such a vaccine, a compelling case can be made for the use of antiviral drugs. First, the treatment of Zika and the prevention of Zika spread might be attained, in part at least, through the use of antiviral drugs to prevent Zika replication within infected individuals. A case can be made for the treatment of both men and women in order to prevent onward spread and transmission of Zika to the A. aegypti mosquito vector.
Although novel drugs need to be investigated in clinical trials prior to approval, hope is provided by the fact that some drugs that have already been approved for other conditions, such as HCV, might also have some anti-Zika activity, as shown here for sofosbuvir. Although the IC 50 of sofosbuvir is probably higher than desirable in regard to the potential use of this agent to combat Zika, our results provide hope that modifications of sofosbuvir may yield compounds that would be far more effective than sofosbuvir itself. In addition, the use of DMB213, while not ideal because of cell toxicity, also provides hope that novel structures, perhaps based on DMB213, might be generated and be able to play a useful role in regard to anti-Zika drug development.
A major finding of this study is the expression and characterization of the Zika RdRp enzyme itself. We are hopeful that this will lead in short order to the crystallization of this enzyme, which may provide further insights into Zika drug development. At the same time, our work has shown that a mutation at position S604T within the RdRp of Zika can confer resistance to sofosbuvir. Moreover, this work has been confirmed in cell-free RdRp assays. This provides testimony to the importance of this mutation across a wide array of RdRp enzymes that are associated with the Flaviviridae family of viruses. Notably, this position seems to be of crucial importance in regard to each of Zika, dengue and HCV.
The work described here is also the first to describe the existence of compounds that might antagonize the replication of ZIKV. Hopefully, this research will shortly kindle new efforts that will lead to the identification of compounds that possess definitive anti-Zika activity and that will be safe and efficacious for human use.
